Inclusion Criteria:

          1. 18-75 years old;

          2. The patient is diagnosed as advanced liver cancer,MUC1/CEA/EpCAM/GPC3 is positive;

          3. There is at least one tumor should be measured,and length≥10mm of focus not at lymph
             node or length≥10mm of focus at lymph node;

          4. C interval of BCLC;

          5. The patient can't tolerate system(systemic chemotherapy/molecular targeted therapy) or
             local therapies;

          6. Child-Pugh Score ≤7;

          7. If the patient received adjuvant chemotherapy after local treatment,the time should be
             more than 4 weeks after the end of chemotherapy, and disease progression or metastasis
             patients can also assigned into the group;

          8. The time of surgical treatment≥ 3 months ;At the end of the intervention, radiotherapy
             and the end of the ablation time is more than 4 weeks;

          9. The expected survival time ≥4 months；

         10. The patient did not took any antitumor drugs within two weeks(any antitumor drugs,
             Chinese patent medicine including Delisheng injection, Kanglaite injection, Aidi
             injection, huaier granule and Ganfule Pian);

         11. ECOG Score ≤1；

         12. HBV DNA<10^4copies/ml（2000IU/ml);

         13. Serum albumin≥28g/L,ALT and AST≤5.0×ULN,TBIL≤1.5×ULN, electrolyte is normal,
             proteinuria = 0 ~ 1 +, serum creatinine≤1.5 x ULN;

         14. Tests of blood,liver and kidney should meet the following
             criteria:WBC≥3×10^9/L,NEUT≥1×10^9/L,Hemoglobin ≥90 g/L,ANC≥1.5×109/L,PLT≥50×10^9/L;

         15. No serious disease are conflicts with the solution(such as autoimmune
             disease,immunodeficiency,orgen transplantation);

         16. Sign the informed consent;

        Exclusion Criteria:

          1. Severe cirrhosis, medium or above ascites;

          2. Cancer embolus in the main portal vein and first branch, Hepatic duct and first
             branch, hepatic vein, inferior vena cava;;

          3. Patients of T cell lymphoma、myeloma,and patients are using immunosuppressant;

          4. Systemic autoimmune diseases, allergic constitution or immunocompromised patients.

          5. Patients of chronic diseases need immune stimulant or hormone therapy ;

          6. Patients of active bleeding or coagulant function
             abnormality（PT>16s、APTT>43s、TT>21s、INR≥2）,and patients of bleeding tendency or are
             receiving thrombolysis and anticoagulation and antiplatelet therapy;

          7. Women who is pregnant or during breast feeding or plan to pregnant in 2 years,and not
             willing to contraception during the test;

          8. Any significant clinical and laboratory abnormalities, the researchers think that
             affect the safety, such as: incontrollable active infection (> NCI - CTC AE v4.0
             standard level 2), uncontrolled diabetes (> level 2 of NCI - CTC AE v4.0 ),
             hypertension and can't be controlled by two or less hypotensor(systolic pressure < 140
             mmHg, diastolic pressure < 90 mmHg), grade II or above peripheral neuropathy (NCI CTC
             AE v4.0), grade II or above congestive heart failure (NCI CTC AE v4.0), myocardial
             infarction in 6 month, thyroid dysfunction (> level 2 of NCI - CTC AE v4.0), etc;

          9. Patients with brain、dura mater metastases or history of psychogeny;

         10. Gastrointestinal bleeding in the past six months or have clear gastrointestinal
             bleeding tendency,such as: patients of local active ulcerative lesions, defecate
             occult blood + + above shall not enter into group; defecate occult blood + depend on
             gastroscopy;

         11. Patients with severe stomach/esophageal varices and need for intervention treatment;

         12. Patients with abdominal fistula, gastrointestinal perforation or abdominal abscess
             within 4 weeks before the first treatment;

         13. Patients with glomenrular filtration rate abnormal obviously(The endogenous creatinine
             clearance < 60 ml/min or serum creatinine > 1.5 x ULN);

         14. Positive for HIV antibody;

         15. Patients who are allergic to computed tomography (CT) and magnetic resonance imaging
             (MRI) contrast agents at the same time, can't imaging assay;

         16. Patients accepted any experimental drugs or pilot medical apparatus and instruments in
             the past 4 weeks of first treatment;

         17. Other reasons the researchers think not suitable.